Rimegepant

Nurtec ODT treats acute migraine with or without aura in adults and prevents episodic migraine in adults. Pediatric safety/effectiveness is unestablished. The preventive indication is episodic migraine; do not broaden it to all chronic migraine or other headache disorders. This reference covers the U.S. 75-mg orally disintegrating product.

Evaluate the migraine diagnosis, disability and response to acute or preventive therapy. Label studies establish selected trial outcomes, not guaranteed relief for every attack. New or atypical severe headache or neurologic symptoms require clinical assessment rather than automatic additional doses.

Take with or without food. Do not double an ODT or use two regimens to exceed the daily maximum. Interacting drugs can require a longer gap than the ordinary daily limit.

Use dry hands to peel back the foil of one blister; do not push the tablet through. Place it on or under the tongue, where it dissolves without water. Take immediately after opening, and do not store the removed ODT for later. A conventional swallowed tablet or another gepant cannot be substituted by milligram arithmetic.

No adjustment is needed for mild/moderate hepatic impairment or mild/moderate/severe renal impairment. Avoid severe hepatic impairment (Child–Pugh C) and end-stage renal disease with CrCl <15 mL/min; dialysis has not been studied. Strong CYP3A4 inhibitors and strong/moderate CYP3A inducers should be avoided rather than solved by an invented reduced ODT dose.

History of hypersensitivity to rimegepant, Nurtec ODT or any component is the formal contraindication. Organ-impairment and interacting-drug avoidance instructions retain their actual precaution/dosing classifications.

The current selected Nurtec ODT label has no boxed warning. Its serious allergy, hypertension and Raynaud warnings still require active review.

Acute-use trials most commonly report nausea; preventive trials commonly report nausea and abdominal pain/dyspepsia. Serious hypersensitivity can occur, and hypertension/Raynaud are postmarketing reports whose frequency cannot be reliably estimated. Suspected overdose requires supportive care and vital-sign/clinical monitoring; dialysis is unlikely to remove much rimegepant because of high protein binding.

Avoid strong CYP3A4 inhibitors. With moderate CYP3A4 inhibitors, avoid another Nurtec dose within 48 hours; label data include fluconazole. With potent P-gp inhibitors—examples include amiodarone, cyclosporine, lapatinib, quinidine and ranolazine—also avoid another dose within 48 hours. Review the whole medication list and both products’ restrictions; an example medicine may have additional contraindications of its own.

Avoid strong or moderate CYP3A inducers because markedly lower rimegepant exposure can cause loss of efficacy. CYP2C9 is a minor metabolic pathway; do not invent a CYP2C9-based adjustment. Label interaction studies without significant PK changes for selected contraceptives, midazolam, metformin or sumatriptan do not establish that every combination is appropriate for every patient.

Adequate human developmental-risk data are unavailable. Animal developmental findings at higher exposures included effects associated with maternal toxicity; these do not quantify human risk. Discuss clinical need and alternatives. A pregnancy exposure registry is available through the label at 1-877-366-0324 or nurtecpregnancyregistry.com.

A single-dose 75-mg study in 12 healthy lactating adults, 2 weeks–6 months postpartum, found relative infant dose <1% and milk/plasma ratio 0.20. Milk transfer is low, but effects on a breastfed infant and milk production remain unknown. Balance breastfeeding benefits, maternal treatment need and infant factors; do not call infant safety proven by this single-dose study.

Pediatric safety/effectiveness is unestablished. Clinical studies had insufficient adults ≥65 to establish a different response, although clinically significant age-related PK differences were not found. No renal adjustment is required above the end-stage avoidance category; avoid CrCl <15 mL/min, with dialysis unstudied. Mild/moderate liver impairment needs no adjustment; severe Child–Pugh C should be avoided because exposure is substantially higher.

Rimegepant is a calcitonin gene-related peptide receptor antagonist. The relationship between pharmacodynamic activity and its clinical mechanism of effect is not fully defined in the label. Mechanistic comparisons do not negate the current BP/Raynaud warnings or establish suitability for all cardiovascular disease.

Peak concentration occurs at about 1.5 hours; absolute oral bioavailability is approximately 64%. Rimegepant is approximately 96% protein-bound and is metabolized primarily by CYP3A4, with a smaller CYP2C9 contribution. It is a P-gp/BCRP substrate. Elimination half-life is about 11 hours; fecal and urinary elimination contribute. Severe hepatic impairment and certain inhibitors increase exposure.

Review migraine type, attack burden and response, total monthly doses, preventive adherence and the medication list. Check organ function when clinically relevant to avoidance categories. Monitor for new/worsening BP and Raynaud symptoms, particularly with prior vascular symptoms. The label supplies no universal serum-level target or routine laboratory interval. Persistent symptoms or frequent dosing require reassessment rather than exceeding the documented safety range.

Keep ODTs in their blister until immediately used; peel foil with dry hands and dissolve on/under the tongue without water. Maximum is one 75-mg dose in 24 hours, and selected interactions require at least a 48-hour repeat gap. Follow the prescribed every-other-day prevention plan and discuss attack-day treatment within limits. Seek urgent care for allergy, even if delayed, and contact the clinician for rising BP. Stop and seek review for painful/cold/discolored digits suggesting Raynaud. Discuss pregnancy, lactation and all co-medications.

Pfizer Nurtec ODT tablets are white to off-white and circular, with the label’s identifying symbol. A carton contains a blister pack of eight 75-mg ODTs, NDC 72618-3000-2. Verify the package rather than using appearance alone.

Each ODT delivers 75 mg rimegepant, equivalent to 85.7 mg rimegepant sulfate (hemisulfate sesquihydrate). There is no covered lower-strength tablet or injectable route. Other CGRP antagonists have separate formulations, approvals and dose limits.

Store at 20–25°C, with excursions 15–30°C. Preserve each ODT in its blister until ready to take, then administer immediately. Keep secure from children and do not retain a removed ODT for later.